Evaluating Asymmetric Dimethylarginine (ADMA) as a Biomarker for Preeclampsia: A Meta-Analysis
DOI:
https://doi.org/10.52783/jns.v14.1599Keywords:
Preeclampsia, asymmetric dimethylarginine (ADMA), meta-analysisAbstract
Background: Preeclampsia (PE) is a serious pregnancy-related disorder characterized by hypertension, endothelial dysfunction, and multi-organ involvement. Despite advances in understanding its pathophysiology, early diagnosis and reliable biomarkers remain critical challenges. Asymmetric dimethylarginine (ADMA) is a natural inhibitor of nitric oxide synthase (NOS) that has been implicated in endothelial dysfunction, a key feature of PE. This study aims to evaluate the potential of ADMA as an early biomarker for the detection and assessment of preeclampsia.
Methods: This systematic review and meta-analysis included 16 observational studies examining the association between serum ADMA levels and preeclampsia. Data from 767 women with PE and 896 healthy controls were analyzed to determine the mean difference in ADMA levels between the two groups. The analysis followed PRISMA guidelines, and heterogeneity was assessed using the I² statistic.
Results: The pooled analysis revealed that serum ADMA levels were significantly higher in women with preeclampsia compared to healthy pregnant controls (mean difference = 0.38 µmol/L, 95% CI: 0.11–0.65 µmol/L, p = 0.01). Significant heterogeneity (I² = 99.9%) was observed across studies. Funnel plots indicated no significant publication bias.
Conclusion: Elevated ADMA levels are associated with preeclampsia and may serve as a promising biomarker for early detection and disease severity evaluation. Despite significant heterogeneity across studies, the findings suggest ADMA's potential role in the pathophysiology of PE, particularly in endothelial dysfunction. Further prospective studies and standardization of measurement techniques are required to confirm ADMA’s clinical utility in preeclampsia diagnosis and management.
Downloads
Metrics
References
Duley L. The Global Impact of Pre-eclampsia and Eclampsia. Semin Perinatol. 2009 Jun;33(3):130–7.
Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol. 2019 May 1;15(5):275.
Guida JP de S, Surita FG, Parpinelli MA, Costa ML. Preterm Preeclampsia and Timing of Delivery: A Systematic Literature Review. RBGO Gynecology & Obstetrics. 2017 Nov 1;39(11):622.
Gusella A, Martignoni G, Giacometti C. Behind the Curtain of Abnormal Placentation in Pre-Eclampsia: From Molecular Mechanisms to Histological Hallmarks. International Journal of Molecular Sciences 2024, Vol 25, Page 7886. 2024 Jul 18;25(14):7886.
Kornacki J, Olejniczak O, Sibiak R, Gutaj P, Wender-Ożegowska E. Pathophysiology of Pre-Eclampsia—Two Theories of the Development of the Disease. International Journal of Molecular Sciences 2024, Vol 25, Page 307. 2023 Dec 25;25(1):307.
Manoharan MM, Montes GC, Acquarone M, Swan KF, Pridjian GC, Alencar AKN, et al. Metabolic theory of preeclampsia: implications for maternal cardiovascular health. https://doi.org/101152/ajpheart001702024. 2024 Sep 1;327(3):H582–97.
Chiang YT, Seow KM, Chen KH. The Pathophysiological, Genetic, and Hormonal Changes in Preeclampsia: A Systematic Review of the Molecular Mechanisms. International Journal of Molecular Sciences 2024, Vol 25, Page 4532. 2024 Apr 20;25(8):4532.
Sibal L, Agarwal SC, Home PD, Boger RH. The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Curr Cardiol Rev. 2010 Apr 22;6(2):82.
NARİN TONGAL S, PİŞKİN İ etem, AYDEMİR C, ARIKAN İİ, CAN M. Asymmetric Dimethyl Arginine and Oxidant/Antioxidant Level in Preeclamptic Mothers and Their Babies. Batı Karadeniz Tıp Dergisi. 2023 Aug 31;7(2):112–9.
Inandiklioglu N, Baser E, Kirmizi DA. Endocan and asymmetric dimethylarginine as an etiological indicator in the maternal and umbilical cord serum in pre-eclampsia. Haseki Tip Bulteni. 2021;59(4):308–12.
Akçal T, Güler Şahin H, Uçkan K. Uçkan K (2021) Serum Asymmetric Dimethylarginine (ADMA) and Nitric Oxide (NO) : Their Pathophysiological Role in Patients with Preeclampsia and HELLP Syndrome. J Fertil In vitro IVF Worldw Reprod Med Genet Stem Cell Biol. 2021;9:4.
Selanno JF, Riu DS, Tessy T, Chalid MT, Pelupessy NU, Hartono E. Maternal serum levels of asymmetric dimethylarginine in normal and preeclamptic pregnancies. Gynecological Endocrinology. 2020 Aug 2;36(8):702–4.
Maruta E, Wang J, Kotani T, Tsuda H, Nakano T, Imai K, et al. Association of serum asymmetric dimethylarginine, homocysteine, and L-arginine concentrations during early pregnancy with hypertensive disorders of pregnancy. Clinica Chimica Acta. 2017 Dec 1;475:70–7.
Laskowska M, Laskowska K, Oleszczuk J. The relation of maternal serum eNOS, NOSTRIN and ADMA levels with aetiopathogenesis of preeclampsia and/or intrauterine fetal growth restriction. Journal of Maternal-Fetal and Neonatal Medicine. 2015 Jan 1;28(1):26–32.
Laskowska M, Laskowska K, Oleszczuk J. Differences in the Association between Maternal Serum Homocysteine and ADMA Levels in Women with Pregnancies Complicated by Preeclampsia and/or Intrauterine Growth Restriction. Hypertens Pregnancy. 2013;32(1):83–93.
Laskowska M, Laskowska K, Terbosh M, Oleszczuk J. A comparison of maternal serum levels of endothelial nitric oxide synthase, asymmetric dimethylarginine, and homocysteine in normal and
Laskowska M, Laskowska K, Oleszczuk J. PP135. Maternal serum levels of endothelial nitric oxide synthase and ADMA, an endogenous ENOS inhibitor in pregnancies complicated by severe preeclampsia. Pregnancy Hypertens. 2012 Jul;2(3):312.
Demir B, Demir S, Pasa S, Guven S, Atamer Y, Atamer A, et al. The role of homocysteine, asymmetric dimethylarginine and nitric oxide in pre-eclampsia. J Obstet Gynaecol (Lahore). 2012 Aug;32(6):525–8.
Laskowska M, Laskowska K, Leszczyńska-Gorzelak B, Oleszczuk J. Asymmetric dimethylarginine in normotensive pregnant women with isolated fetal intrauterine growth restriction: A comparison with preeclamptic women with and without intrauterine growth restriction. Journal of Maternal-Fetal and Neonatal Medicine. 2011 Jul;24(7):936–42.
Turan F, Ilhan N, Kaman D, Ateş K, Kafkasli A. Glu298Asp polymorphism of the endothelial nitric oxide synthase gene and plasma concentrations of asymmetric dimethylarginine in Turkish pre-eclamptic women without fetal growth retardation. Journal of Obstetrics and Gynaecology Research. 2010;36(3):495–501.
2Mao D, Che J, Li K, Han S, Yue Q, Zhu L, et al. Association of homocysteine, asymmetric dimethylarginine, and nitric oxide with preeclampsia. Arch Gynecol Obstet. 2010 Oct;282(4):371–5.
Braekke K, Ueland PM, Harsem NK, Staff AC. Asymmetric Dimethylarginine in the Maternal and Fetal Circulation in Preeclampsia. Vol. 66, Pediatr Res. 2009.
23Gh Al-Rubaye F. ADMA) level in Serum of Preeclamptic patients Faisal Gh. Al-Rubaye. Vol. 51, J Fac Med Baghdad. 2009.
Herrmann W, Isber S, Obeid R, Herrmann M, Jouma M. Concentrations of homocysteine, related metabolites and asymmetric dimethylarginine in preeclamptic women with poor nutritional status. Clin Chem Lab Med. 2005 Oct;43(10):1139–46.
McElwain CJ, Tuboly E, McCarthy FP, McCarthy CM. Mechanisms of Endothelial Dysfunction in Pre-eclampsia and Gestational Diabetes Mellitus: Windows Into Future Cardiometabolic Health? Front Endocrinol (Lausanne). 2020 Sep 11;11:569593.
Böger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the “L-arginine paradox” and acts as a novel cardiovascular risk factor. Journal of Nutrition. 2004;134(10 SUPPL.).
Guerby P, Tasta O, Swiader A, Pont F, Bujold E, Parant O, et al. Role of oxidative stress in the dysfunction of the placental endothelial nitric oxide synthase in preeclampsia. Redox Biol. 2021 Apr 1;40:101861.
Allotey J, Snell KIE, Smuk M, Hooper R, Chan CL, Ahmed A, et al. Validation and development of models using clinical, biochemical and ultrasound markers for predicting pre-eclampsia: an individual participant data meta-analysis. Health Technol Assess (Rockv). 2020 Dec 18;24(72):1–252.
Chen X, Yuan L, Ji Z, Bian X, Hua S. Development and validation of the prediction models for preeclampsia: a retrospective, single-center, case-control study. Ann Transl Med. 2022 Nov;10(22):1221.
Speer PD, Powers RW, Frank MP, Harger G, Markovic N, Roberts JM. Elevated asymmetric dimethylarginine concentrations precede clinical preeclampsia, but not pregnancies with small-for-gestational-age infants. Am J Obstet Gynecol. 2008;198(1):112.e1-112.e7.
Ellis J, Wennerholm UB, Bengtsson A, Lilja H, Pettersson A, Sultan B, et al. Levels of dimethylarginines and cytokines in mild and severe preeclampsia. Acta Obstet Gynecol Scand. 2001;80(7):602–8.
Braekke K, Ueland PM, Harsem NK, Staff AC. Asymmetric Dimethylarginine in the Maternal and Fetal Circulation in Preeclampsia. Vol. 66, Pediatr Res. 2009.
Noorbakhsh M, Kianpour M, Nematbakhsh M. Serum Levels of Asymmetric Dimethylarginine, Vascular Endothelial Growth Factor, and Nitric Oxide Metabolite Levels in Preeclampsia Patients. ISRN Obstet Gynecol. 2013 Sep 11;2013:1–5.
Prefumo F, Thilaganathan B, Whitley GS. First-trimester uterine artery resistance and maternal serum concentration of asymmetric dimethylarginine. Ultrasound in Obstetrics and Gynecology. 2008 Feb;31(2):153–7.
Rijvers CAH, Marzano S, Winkens B, Bakker JA, Kroon AA, Spaanderman MEA, et al. Early-pregnancy asymmetric dimethylarginine (ADMA) levels in women prone to develop recurrent hypertension. Pregnancy Hypertens. 2013 Apr;3(2):118–23.
Yuan X, Cai L, Hu F, Xie L, Chen X, Wu J, et al. Evaluation of the predictive values of elevated serum l-homoarginine and dimethylarginines in preeclampsia. Amino Acids. 2022 Aug 1;54(8):1215–27.
Dymara-Konopka W, Laskowska M. The role of Nitric Oxide, ADMA, and Homocysteine in the etiopathogenesis of preeclampsia—review. Vol. 20, International Journal of Molecular Sciences. MDPI AG; 2019.
Possomato-Vieira JS, Khalil RA. Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia. Adv Pharmacol. 2016;77:361.
Opichka MA, Rappelt MW, Gutterman DD, Grobe JL, Mcintosh JJ, Warrington P, et al. Vascular Dysfunction in Preeclampsia. Cells 2021, Vol 10, Page 3055. 2021 Nov 6;10(11):3055.
Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol. 2014;10(8):466.
Ng KW, Chaturvedi N, Coté GL, Fisher SA, Mabbott S. Biomarkers and point of care screening approaches for the management of preeclampsia. Communications Medicine 2024 4:1. 2024 Oct 22;4(1):1–15.
Oladipo AF;, Jayade M, Oladipo AF, Jayade M. Review of Laboratory Testing and Biomarker Screening for Preeclampsia. BioMed 2024, Vol 4, Pages 122-135. 2024 May 14;4(2):122–35.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
